Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247 Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic a

Exciting news today from Satellos:

can01.safelinks.protection.outlook.com?url=https%3A...

An Ottawa scientist's discovery offers rare hope for patients with devastating genetic disease An Ottawa stem cell researcher's groundbreaking discovery offers rare hope for patients with the genetic disease.

I am very proud of our entire team both in the lab at OHRI and at Satellos who have brought a serendipitous discovery to the point where we are now conducting clinical trials!
can01.safelinks.protection.outlook.com?url=https%3A...